TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15177699

Group type: EXPERIMENTAL
Intervention: rhGH treatment for 3 and 6 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhGH treatment for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment for 3 and 6 months
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhGH treatment in the open-label phase
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment in the open-label phase
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 11165820

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbopol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 10
Study: 9488585

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation with beta-carotene and alpha-tocopherol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7999599

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment 50 micrograms/g twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coal tar solution BP 15% v/w in aqueous cream applied in the evening
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment and Coal tar solution
Number of subjects: 30
Study: 3263379

Group type: EXPERIMENTAL
Intervention: 2.5 mg prednisone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg prednisone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29615028

Group type: EXPERIMENTAL
Intervention: 12-week multicomponent exercise programme (resistance training combined with balance training)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 28465127

Group type: EXPERIMENTAL
Intervention: Multifaceted hand‐washing/surface cleaning intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control NHs
Number of subjects: 10
Study: 26367736

Group type: EXPERIMENTAL
Intervention: Silymarin plus vitamin E (2 tablets per day) and hypocaloric diet (1520 kcal, 52% carbohydrates, 25% lipids, 23% proteins) for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hypocaloric diet only
Number of subjects: 36
Study: 23245336

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m² on day 1) and Cisplatin (25 mg/m² on days 2 and 4) with regional hyperthermia (1 hour on days 2 and 4) biweekly for 4 months
Number of subjects: 23
Study: 22014122

Group type: EXPERIMENTAL
Intervention: Technology-assisted case management using the FORA system coupled with nurse case management
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 19673597

Group type: EXPERIMENTAL
Intervention: Dicloxacillin (1.0 g intravenous dose, 30 min prior to operation)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo (saline infusion, 30 min prior to operation)
Number of subjects: 292
Study: 17022367

Group type: EXPERIMENTAL
Intervention: Cold ceramic
Number of subjects: 40

Group type: COMPARATOR
Intervention: Glass ionomer
Number of subjects: 40
Study: 12644419

Group type: EXPERIMENTAL
Intervention: 50 micro g fentanyl epidurally
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 micro g fentanyl epidurally
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10690937

Group type: EXPERIMENTAL
Intervention: GHRH 50 microg intravenous (IV) injection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Porcine GAL 500 microg infusion from -10 to +30 minutes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 9062857

Group type: EXPERIMENTAL
Intervention: Periocheck
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Perioscan
Number of subjects: 19

Group type: COMPARATOR
Intervention: Composite clinical assessment
Number of subjects: 19
Study: 8456753

Group type: EXPERIMENTAL
Intervention: Hirulog 0.05 mg/kg intravenous bolus followed by 0.2 mg/kg/hour intravenous infusion
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hirulog 0.15 mg/kg intravenous bolus followed by 0.6 mg/kg/hour intravenous infusion
Number of subjects: 45

Group type: COMPARATOR
Intervention: Heparin 5,000 U intravenous bolus
Number of subjects: 45
Study: 2941687

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Second series of vaccinations
Number of subjects: 773
Study: 30281698

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 89

Group type: COMPARATOR
Intervention: Traditional laparoscopic surgery
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 27688075

Group type: EXPERIMENTAL
Intervention: Infants of depressed mothers
Number of subjects: 114

Group type: COMPARATOR
Intervention: Infants of nondepressed mothers
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Disease by biomarker analyses using GeneGo MetaCore Software
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Process networks analysis
Number of subjects: 114
Study: 23913020

Group type: EXPERIMENTAL
Intervention: Selective coiling
Number of subjects: 14

Group type: COMPARATOR
Intervention: Parent artery occlusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Selective coiling and Parent artery occlusion
Number of subjects: 14
Study: 22437068

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (no drug treatment)
Number of subjects: 51
Study: 20386216

Group type: EXPERIMENTAL
Intervention: Mini-implant anchorage
Number of subjects: 14

Group type: COMPARATOR
Intervention: Molar anchorage (non-implant)
Number of subjects: 14
Study: 18343487

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gemcitabine (GEM)
Number of subjects: 30
Study: 15083355

Group type: EXPERIMENTAL
Intervention: Postoperative morphine sulfate plus lidocaine administered as a local spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine applied alone
Number of subjects: 60
Study: 12429761

Group type: EXPERIMENTAL
Intervention: Mechanical compression device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prophylactic stockings
Number of subjects: 100
Study: 10488967

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E phenotype E2 carriers
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E phenotype E4 carriers
Number of subjects: 822

Group type: COMPARATOR
Intervention: Apolipoprotein E phenotype E3/3 homozygotes
Number of subjects: 822
Study: 8709630

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy according to NOPHO AML protocols
Number of subjects: 20

Group type: COMPARATOR
Intervention: Allogeneic bone marrow transplantation (BMT) without prior chemotherapy
Number of subjects: 20
Study: 2008691

Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 7

Group type: COMPARATOR
Intervention: Gluten (provocation)
Number of subjects: 7
Study: 6189439

Group type: EXPERIMENTAL
Intervention: Local corticotherapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Calcitonin, blocking agents, intravenous clomipramine, periarterial injections of local anaesthetics, local or general corticotherapy, physiotherapy, kinesitherapy
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Kinesitherapy
Number of subjects: 130
Study: 31370896

Group type: EXPERIMENTAL
Intervention: Sodium citrate (SC - 0.5 g.kg‐1BM in capsules of 500 mg)
Number of subjects: 10
Study: 28381584

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) with aspirin + a P2Y12 inhibitor
Number of subjects: 9240
Study: 26390721

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (auto-HSCT) after non-myeloablative BEAM conditioning
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chemotherapy (non-auto-HSCT group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-auto-HSCT
Number of subjects: 90
Study: 23958795

Group type: EXPERIMENTAL
Intervention: 0.8 mg/kg of alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 21851764

Group type: COMPARATOR
Intervention: Training intervention for healthcare professionals (HCPs)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 693
Study: 19530070

Group type: EXPERIMENTAL
Intervention: NIR transmission mode
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIR transmission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIR Quantification
Number of subjects: 0
Study: 17261336

Group type: EXPERIMENTAL
Intervention: Periodic postal reminders to see their general practitioner every three months during a 3-year follow-up.
Number of subjects: 983

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 983
Study: 14692040

Group type: EXPERIMENTAL
Intervention: 10-week cognitive-behavioral stress management (CBSM) intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: 1-day seminar (control group)
Number of subjects: 92
Study: 12150516

Group type: EXPERIMENTAL
Intervention: High Bcl-2 expression
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High Bcl-XL expression
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High Bax expression
Number of subjects: 47
Study: 9814091

Group type: EXPERIMENTAL
Intervention: tenoxicam 20 mg daily for six weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: piroxicam 20 mg daily for six weeks
Number of subjects: 48
Study: 7542109

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily for 6 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2649213

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol-17-propionate cream
Number of subjects: 10
Study: 1087383

Group type: EXPERIMENTAL
Intervention: L‐5‐hydroxytryptophan (alone or in combination with carbidopa)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30572162

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavior therapy (CCBT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 240
Study: 26464212

Group type: EXPERIMENTAL
Intervention: Intensive treatment (79% prescribed insulin, mean total daily dose 0.41 units/kg)
Number of subjects: 10163

Group type: COMPARATOR
Intervention: Standard treatment (62% prescribed insulin, mean total daily dose 0.30 units/kg)
Number of subjects: 10163

Group type: EXPERIMENTAL
Intervention: Prandial insulin
Number of subjects: 10163

Group type: EXPERIMENTAL
Intervention: Insulin dose after adjustment for covariates
Number of subjects: 10163
Study: 23542800

Group type: EXPERIMENTAL
Intervention: Protective ventilation strategy (tidal volume of 7 ml/kg ideal body weight, 10 cm H2O positive end-expiratory pressure, and recruitment maneuvers)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard ventilation strategy (tidal volume of 9 ml/kg ideal body weight and zero-positive end-expiratory pressure)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 21771797

Group type: EXPERIMENTAL
Intervention: Hawley retainer (HR)
Number of subjects: 120

Group type: COMPARATOR
Intervention: clear overlay retainer (COR)
Number of subjects: 120
Study: 19874247

Group type: COMPARATOR
Intervention: Antidepressants and hormonal supplements
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Open-label studies
Number of subjects: 19
Study: 17085763

Group type: EXPERIMENTAL
Intervention: Integrated care treatment model
Number of subjects: 8367

Group type: EXPERIMENTAL
Intervention: Treatment initiation
Number of subjects: 8367

Group type: EXPERIMENTAL
Intervention: Predictors of research adherence and treatment initiation
Number of subjects: 8367
Study: 14727010

Group type: EXPERIMENTAL
Intervention: L‐T4 (n=31)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 11758675

Group type: EXPERIMENTAL
Intervention: agalsidase alfa (human alpha‐Gal A)
Number of subjects: 26
Study: 9466067

Group type: EXPERIMENTAL
Intervention: Warfarin continued (17 patients, 85%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Warfarin group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (non-warfarin)
Number of subjects: 20
Study: 7946924

Group type: EXPERIMENTAL
Intervention: Brewer's yeast
Number of subjects: 22

Group type: COMPARATOR
Intervention: Torula yeast
Number of subjects: 22
Study: 3279916

Group type: EXPERIMENTAL
Intervention: 200 mg/kg phospholipid given intratracheally (treatment group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 29
Study: 31487797

Group type: EXPERIMENTAL
Intervention: Kefir (180 mL/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unfermented milk (control)
Number of subjects: 22
Study: 28104555

Group type: EXPERIMENTAL
Intervention: Gossip conversation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Emotional non-gossip conversation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Neutral conversation
Number of subjects: 22
Study: 26025412

Group type: EXPERIMENTAL
Intervention: Contraceptive pill + flare-up GnRH‐agonist protocol (P2)
Number of subjects: 440

Group type: COMPARATOR
Intervention: GnRH‐antagonist protocol (P3)
Number of subjects: 440
Study: 24273972

Group type: EXPERIMENTAL
Intervention: Acupuncture at bilateral Neiguan (PC6) and Xinshu (BL15) for 30 min, frequency of 2/15 Hz, current strength 9 - 18 mA
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nitroglycerine (1 mg sublingual administration)
Number of subjects: 59
Study: 22005860

Group type: COMPARATOR
Intervention: Independent exercises
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 94
Study: 19484202

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide (1‐34 PTH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1‐84 PTH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of two or more drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTH followed by bisphosphonates
Number of subjects: 0
Study: 16430313

Group type: EXPERIMENTAL
Intervention: Ximelagatran (12, 24, 36, and 60mg on separate days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ximelagatran (12, 24, and 36mg on separate days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 14634679

Group type: EXPERIMENTAL
Intervention: Orlistat and lifestyle modification (OLM)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 108
Study: 10607279

Group type: EXPERIMENTAL
Intervention: Structured Question Grid
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 67
Study: 8626358

Group type: EXPERIMENTAL
Intervention: Nefazodone (200 to 600 mg/day)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Imipramine (100 to 300 mg/day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (2 to 6 capsules/day)
Number of subjects: 128
Study: 1627372

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (300 micrograms/m2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interleukin-2 (300 micrograms/m2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interleukin-2
Number of subjects: 22
Study: 6201999

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both TURP and TVP
Number of subjects: 75
Study: 31234642

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Eptinezumab 30 mg
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Eptinezumab 10 mg
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 29363715

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 27334131

Group type: EXPERIMENTAL
Intervention: NEPA + DEX
Number of subjects: 196

Group type: COMPARATOR
Intervention: APR + PALO + DEX
Number of subjects: 196
Study: 24269255

Group type: COMPARATOR
Intervention: Fasted/Food Absence
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fasted/Food Exposure
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fed/Food Absence
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Fed/Food Exposure
Number of subjects: 67
Study: 22465890

Group type: EXPERIMENTAL
Intervention: Intravenous erythropoietin (20,000 unit/24 hours) for 5 consecutive days along with intravenous methyl prednisolone (1000 mg/24 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous methyl prednisolone (1000 mg/24 hours) and placebo
Number of subjects: 10
Study: 20526703

Group type: EXPERIMENTAL
Intervention: CLD 100 mg IM weekly for 12 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CLD 200 mg IM every 2 weeks for 12 months
Number of subjects: 60
Study: 17964398

Group type: EXPERIMENTAL
Intervention: AcrySof IQ IOL
Number of subjects: 25

Group type: COMPARATOR
Intervention: AcrySof Natural IOL
Number of subjects: 25
Study: 11703042

Group type: EXPERIMENTAL
Intervention: Intervention group T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group S
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group C
Number of subjects: 0
Study: 9220520

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 92

Group type: COMPARATOR
Intervention: No maintenance therapy (Control)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Serum ECP > or = 16 micrograms/L
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Serum ECP < 16 micrograms/L
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Serum ECP > or = 8 micrograms/L
Number of subjects: 92
Study: 8427515

Group type: EXPERIMENTAL
Intervention: 600 mg/day tiludronate for five days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 800 mg/day tiludronate for five days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1200 mg/day tiludronate for five days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study: 3113413

Group type: EXPERIMENTAL
Intervention: Fat emulsion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Simple electrolyte solutions or isocaloric parenteral regimes without fat emulsion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dextrose or amino acid solutions
Number of subjects: 15
Study: 29177979

Group type: EXPERIMENTAL
Intervention: Diode laser and topical treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topical treatment only
Number of subjects: 15
Study: 28146007

Group type: EXPERIMENTAL
Intervention: Isokinetic training 3 days a week for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 31
Study: 26682606

Group type: EXPERIMENTAL
Intervention: Self-controlled feedback
Number of subjects: 36

Group type: COMPARATOR
Intervention: Yoked with self-controlled feedback
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Limited self-controlled feedback
Number of subjects: 36
Study: 23193209

Group type: EXPERIMENTAL
Intervention: LY2605541
Number of subjects: 137

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 137
Study: 21512887

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 93
Study: 18291017

Group type: EXPERIMENTAL
Intervention: Hypoechoic lesion-directed biopsy
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Systematic sextant biopsy
Number of subjects: 1840

Group type: COMPARATOR
Intervention: Repeat and third screening
Number of subjects: 1840
Study: 16188911

Group type: EXPERIMENTAL
Intervention: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1) with a dairy breakfast
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3-h intravenous infusion of saline with a dairy breakfast
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 3-h intravenous infusion of saline
Number of subjects: 15
Study: 12657991

Group type: EXPERIMENTAL
Intervention: 2 mg of tropisetron
Number of subjects: 65

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 65
Study: 10747265

Group type: EXPERIMENTAL
Intervention: Oral piroxicam 1 mg/kg/day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Soluble aspirin 100 mg/kg/day taken four-hourly
Number of subjects: 58
Study: 8936562

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered immediately after fluoxetine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered 2 hours after fluoxetine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g) administered 4 hours after fluoxetine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluoxetine on an empty stomach with water only
Number of subjects: 32
Study: 1539484

Group type: EXPERIMENTAL
Intervention: labetalol 0.5 mg.kg‐1 i.v. in addition to isoflurane
Number of subjects: 24

Group type: COMPARATOR
Intervention: isoflurane 3.0 vol% in inspiratory gas
Number of subjects: 24